^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | sirolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
Excerpt:
...inhibiting mTOR using rapamycin had a more pronounced affect on proliferation in LKB1/KRAS mutant cell lines; in this case, the sensitive cluster also included the LKB1/BRAF mutant cell line CAL12T. The IC50 of the LKB1/MAPK mutant cluster was significantly different from the control cluster (40 nM vs >100 nM, P⩽0.04)...
